Actively induced immunotherapy is one of the most promising fields in cancer research and numerous approaches are being studied to design effective cancer vaccines. Among the treatment strategies to develop an effective immune response against tumor associated antigens is the use of anti idiotype (Ab2) mAb as antigen surrogates. Several studies in animal models have demonstrated the efficacy of these vaccines for triggering the immune system to induce specific and protective immunity against tumors of different origin. In fact, anti-idiotypic mAbs have been used successfully in cancer therapeutics to overcome the poor immunogenicity of some tumor-associated antigens, in particular those of non-protein origin. In some clinical trials, including patients with different tumors, anti-Id specific humoral and/or cellular responses following immunization were associated with improved clinical outcome. This number of Frontiers will be dedicated to anti- idiotypic antibodies and their use in cancer treatment. Different article types will be considered: original contributions, case reports, methods, hypothesis and theory, reviews, historical, etc.

Present knowledge in regional cancer therapy is presented in this volume. The latest research addresses the questions of optimal drug development, the best galenic form and schedule to control tissue distribution at the tumor site and efficient treatment of specific anatomical regions.

Epigenetic Regulation of Cancer in Response to Chemotherapy, Volume 158 of the Advances in Cancer Research series, highlights new advances in the field, with this new volume presenting chapters on timely topics, including Epigenetically Programmed Resistance to Chemotherapy and Promotion of Immune Evasion in Cancer, A Role for the Epigenome in Cancer Cell Drug Tolerance, Histone Methylation and X Chromosomal Genes in Metastasis of Breast Cancer, Targeting Epigenetic Regulation Using Small Molecule Inhibitors, Histone Deacetylase Inhibitors as Sanguine Epigenetic Therapeutics against Pugnacious Lung Cancer, From ecology to oncology: To understand cancer stem cell dormancy, ask a Brine shrimp (Artemia), and more. Additional chapters cover Predictive Models of Chemoresistance Generated by Crunching the Public Drug Screen, Epigenomic and Genomic Profiling Datasets via Regression-, Machine Learning, and Knowledge-Based Methods, Probing on the Mechanisms of lncRNAs on Cancer Drug Resistance, Drug Tolerant Persister Cells in Cancer: Current Knowledge and Therapeutic Perspectives, and much more. - Provides the authority and expertise of leading contributors from an international board of authors - Presents the latest release in the Advances in Cancer Research series - Includes the latest information on the Epigenetic Regulation of Cancer in Response to Chemotherapy

Cancer still poses a significant challenge in healthcare since traditional treatments often fail to produce desired results and patient outcomes. Conventional therapies, like chemotherapy and radiation, can have substantial side effects and may not always be able to eliminate cancer cells. Moreover, the heterogeneity of tumors and individual responses to treatment create barriers to achieving consistent and long-lasting outcomes. Critical Developments in Cancer Immunotherapy offers a compelling solution to these challenges by delving into the cutting-edge field of cancer immunotherapy. This book provides a comprehensive guide to the latest advancements in harnessing the body's immune system to fight cancer. Focusing on critical strategies like checkpoint inhibitors and CAR T-cell therapy, the book provides insights into novel approaches that offer greater precision and effectiveness in cancer treatment.

This translational book describes in detail the clinical application of novel approaches in cancer immunotherapy with the aim of educating clinicians in the implications of the most recent research and new developments in the field. The scope is broad, encompassing, for example, prognostic biomarkers for personalized cancer treatment, strategies for targeting tumor immunosuppression, gene therapy, virus-based vaccines, targeting of cancer stem cells, hematopoietic stem cell transplantation, the role of T lymphocytes in cancer immunotherapy, use of monoclonal antibodies, and many more innovative approaches. Clinical immunologists, hematologists, and oncologists in particular will find the book to be of value in expanding their knowledge. The book is the second in a three-volume series, Cancer Immunology, which offers an up-to-date review of cancer immunology and immunotherapy. The remaining volumes focus on the immunopathology of cancers and cancer immunotherapy for organ-specific tumors. In total the series, designed for both clinicians and researchers, includes contributions from more than 250 scientists working at leading universities and institutes from across the world.

Adenocarcinomas: New Insights for the Healthcare Professional: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Diagnosis and Screening. The editors have built Adenocarcinomas: New Insights for the Healthcare Professional: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Diagnosis and Screening in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Adenocarcinomas: New Insights for the Healthcare Professional: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.